

## Disclosures

### Personal Commercial (0)

No disclosures on record

### Additional Personal Commercial Disclosures for Education Activities (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
alivecor	Research/Research Grants ‡ ST LEUIS II	None (\$0)	Acute Coronary Syndromes
Amarin	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
esperion	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Idorsia	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
irhythm	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ Understanding PAD management patterns in an integrated healthcare system to identify opportunities to improve clinical outcomes in overall ASCVD risk reduction and management with a focus on PAD.	None (\$0)	Vascular Medicine
Lexicon Pharmaceuticals	Consultant Fees/Honoraria	None (\$0)	General Cardiology
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

### Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Academy of PAs in Cardiology	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	General Cardiology
American Academy of Physician Associates	Other - Social Media Ambassador	None (\$0)	Other
Octavian Solutions	Other - Chief Medical Officer	Significant (>= \$5,000)	Other
Utah Academy of PAs	Other - Immediate Past President 2025-2026	None (\$0)	Other

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 3/31/2026

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.